Theramex Faces Backlash for HRT Drug Safety Lapses

0:00On April 22nd, Theromex, a major U.K. maker of hormone replacement therapy drugs like Everell Patches and Interrosa, just got hit with a public smackdown, from the prescription medicine's code of practice authority. They found systemic failures and compliance that straight up risked patient safety, like not updating key prescribing info for years and skipping clear. Warnings that some drugs can't be used during pregnancy. Whistleblowers inside the company flagged these alarming gaps, including missing side-effect details for Everell and no updates to Interrosa's info since 2019. Theromex also messed up as for their uterine fibroid drug-wise salty by not mentioning the pregnancy, no go. Everell is one of the top-transdermal HRT options, with over 250,000 items prescribed last year, part of nearly 10 million, estradiol prescriptions overall. These 21 code breaches not only endangered folks, but dragged down trust in the whole pharma game. The regulator ripped Theromex for bailing on their self-policing system, shifting oversight

1:03to the medicines and healthcare products regulatory agency, and slowing things down. ABPI's medical director called it a serious shortfall, while MHRA vowed to step up for safety. Theromex claims they jumped on fixes with audits and reviews, opting for MHRA rules to sharpen their compliance edge while keeping patient safety. This saga underscores why sharp oversight stays crucial in meds that millions rely on daily.